Lecture: Amino Acid Transport

Amino Acid Transport: why there isn’t one transporter per amino acid

Cells bring in amino acids through families of transporters that share duties. One amino acid is usually handled by several carriers, and each carrier accepts a set of amino acids. This shared approach gives cells flexibility during fasting, feeding, growth, and stress. It also explains many clinical findings, from inherited transport disorders to the way tumors upregulate specific carriers.

How transport works in broad strokes

A transporter sits in the cell membrane and moves amino acids by one of three strategies. A uniporter provides a channel-like pathway for an amino acid to move down its gradient. A symporter couples amino acid entry to the inward movement of an ion such as sodium or a proton. An antiporter swaps one amino acid for another across the membrane. The gradients that power these moves come from pumps such as the sodium potassium ATPase and from pH differences across membranes.

Sodium gradients are key in gut and kidney where epithelial cells face large swings in nutrient supply. Proton gradients help in parts of the small intestine and lysosome. Exchange mechanisms are common in tissues that need to trade one amino acid for another to keep metabolism balanced.

Why the old “system” names still matter

Before genes were cloned, physiologists grouped transport activities into “systems” based on the amino acids transported, ion coupling, and sensitivity to inhibitors. The classic list includes system L, A, ASC, N, y+, y+L, b0,+, B0, and the acidic amino acid system often labeled XAG. Modern gene names map these systems to solute carrier families known as SLC genes. Both naming schemes are still used. Knowing both helps you read papers across eras.

Large neutral amino acids and system L

System L moves bulky neutral amino acids such as leucine, isoleucine, valine, phenylalanine, tyrosine, tryptophan, and methionine. LAT1 and LAT2 are the best known members.

LAT1 is encoded by SLC7A5 and forms a heterodimer with the heavy chain 4F2hc, encoded by SLC3A2. The heavy chain is required for proper trafficking to the membrane. LAT1 works without sodium and functions mainly as an exchanger. It swaps one neutral amino acid inside the cell for another outside. LAT1 is abundant at the blood brain barrier and in many tumors. Its transport of leucine is tied to mTORC1 activation because intracellular leucine availability is one of the key signals for protein synthesis. Many cancer cells raise LAT1 levels to feed growth with essential amino acids.

LAT2, encoded by SLC7A8, also pairs with 4F2hc. It is common in kidney and small intestine on the basolateral side. LAT2 helps neutral amino acids leave epithelial cells into the blood after apical uptake. LAT3 and LAT4, encoded by SLC43A1 and SLC43A2, are facilitative carriers for large neutral amino acids that do not need sodium and do not require a heavy chain partner. These carriers contribute in liver, muscle, and placenta.

Sodium coupled neutral amino acid transport: systems A and N

System A transporters SNAT1, SNAT2, and SNAT7 are encoded by SLC38A1, SLC38A2, and SLC38A7. They use the inward sodium gradient to take up small neutral amino acids such as alanine, serine, threonine, cysteine, asparagine, and glutamine. SNAT2 is strongly upregulated during amino acid starvation and is a major player in many cultured cells. When SNAT2 rises, intracellular amino acid pools recover and mTORC1 signaling can restart. This response is linked to the ATF4 transcription program and the GCN2 stress pathway.

System N transporters SNAT3 and SNAT5, encoded by SLC38A3 and SLC38A5, also couple to sodium but exchange protons. They specialize in glutamine and histidine and play major roles in liver and brain astrocytes where shuttling of glutamine supports the glutamate glutamine cycle. Their proton coupling gives them unique pH sensitivity that fits their roles in tissues with variable acid load.

ASCT2 and the SLC1 family

SLC1A5, often called ASCT2, transports neutral amino acids and is best known for moving glutamine through an exchange process. Many tumor studies report high ASCT2 expression, since glutamine fuels anaplerosis, nucleotide synthesis, and redox control. The SLC1 family also includes the high affinity excitatory amino acid transporters that clear glutamate and aspartate from synapses. These are listed below with their own section because they have distinct functions and stoichiometry.

Cationic amino acids: systems y+ and y+L

Lysine and arginine carry positive charge at physiological pH and need their own routes.

System y+ carriers CAT1, CAT2, and CAT3 are encoded by SLC7A1, SLC7A2, and SLC7A3. They move cationic amino acids without sodium. CAT1 is ubiquitous and provides high affinity uptake for arginine and lysine. Immune cells rely on CAT transport to supply arginine for nitric oxide synthase and for growth.

System y+L transporters y+LAT1 and y+LAT2, encoded by SLC7A7 and SLC7A6, form heterodimers with 4F2hc. They exchange cationic amino acids for neutral amino acids in a sodium dependent manner on the basolateral membrane of intestine and kidney. Loss of SLC7A7 causes lysinuric protein intolerance. Patients have poor absorption and reabsorption of cationic amino acids, leading to failure to thrive, hyperammonemia after meals rich in protein, and long term complications without careful management.

Brush border specialists in gut and kidney

Neutral amino acids from the lumen enter enterocytes using B0AT1, encoded by SLC6A19. This is a sodium coupled transporter with broad specificity for neutral amino acids. ACE2 and collectrin serve as auxiliary factors that help B0AT1 fold and reach the apical membrane. Mutations in SLC6A19 cause Hartnup disorder, which leads to poor transport of neutral amino acids and pellagra like symptoms when the diet is marginal in niacin.

Dipeptides and tripeptides use PEPT1, encoded by SLC15A1. This carrier uses the proton gradient to move small peptides into the cell. Cytosolic peptidases then release free amino acids. This pathway is a big reason many protein hydrolysates and peptide bound drugs absorb well even when single amino acid transporters appear saturated.

Cystine and basic amino acids enter from the lumen through the b0,+ transporter, a heterodimer formed by b0,+AT encoded by SLC7A9 and rBAT encoded by SLC3A1. Loss of this pathway causes cystinuria. Patients form kidney stones because cystine is poorly soluble and spills into urine.

Acidic amino acids and synaptic protection

Excitatory amino acid transporters EAAT1 to EAAT5, encoded by SLC1A3, SLC1A2, SLC1A1, SLC1A6, and SLC1A7, clear glutamate and aspartate from the extracellular space, especially around synapses. Their stoichiometry is unusual and tight. Each transport cycle moves one glutamate with three sodium ions and one proton into the cell while one potassium ion moves out. This sets up powerful uptake even when extracellular glutamate is low. Astrocytic EAAT1 and EAAT2 prevent excitotoxicity by keeping synaptic glutamate near micromolar levels. Mutations or downregulation of these carriers are linked with seizures and neurodegeneration in several models.

Cystine uptake and redox control

The xCT transporter, encoded by SLC7A11, exchanges extracellular cystine for intracellular glutamate. Once inside, cystine is reduced to cysteine and used for glutathione synthesis. xCT activity supports resistance to oxidative stress. Many tumors elevate xCT, which can create dependence on this route. Blocking xCT can lower glutathione and sensitize cells to ferroptosis, an iron dependent lipid peroxidation form of cell death.

Special cases: glycine, proline, and proton coupled transport

GlyT1 and GlyT2, encoded by SLC6A9 and SLC6A5, control glycine levels near inhibitory synapses and in glia. They are sodium chloride coupled and have very high affinity. In the small intestine a proton coupled transporter called PAT1, encoded by SLC36A1, moves small neutral amino acids. It also carries some orally dosed drugs that resemble small amino acids or dipeptides. Proline and hydroxyproline use SIT1, encoded by SLC6A20, often described in the literature as the IMINO transporter. These carriers complete the set of specialized routes for small or cyclic amino acids.

Membrane sidedness and whole body flow

Polarity matters in epithelia. On the apical side facing the lumen, B0AT1 and b0,+AT take up neutral and basic amino acids using sodium or exchange with other amino acids. On the basolateral side, y+LAT and LAT carriers move amino acids into blood, often by exchange. This division lets the cell collect nitrogen and carbon from the lumen and release them to the body without collapsing gradients.

In most other tissues sodium coupled carriers such as SNATs bring in small neutral amino acids to refill pools for protein synthesis and energy metabolism. System L carriers then exchange intracellular neutral amino acids with the outside world to balance pools with minimal energy cost. These linked steps explain why one amino acid rarely depends on a single carrier.

Control by cell signaling and nutrient sensors

Amino acid sufficiency regulates translation through mTORC1. Leucine sensing involves Sestrin2 and intracellular leucine; arginine sensing involves CASTOR proteins in the cytosol and SLC38A9 at the lysosome. When leucine and arginine are plentiful, Rag GTPases recruit mTORC1 to lysosomes where it becomes active. Low amino acids trigger the GCN2 kinase, which detects uncharged tRNAs and raises ATF4. ATF4 then increases expression of transporters such as SNAT2 and enzymes for amino acid synthesis and recycling. This feedback loop changes both transporter abundance and membrane localization, matching supply with demand.

Inflammatory cytokines, hypoxia, and oxidative stress also reshape the transporter landscape. HIF can raise LAT1 and xCT. NRF2 can raise xCT through the antioxidant response element. Insulin and IGF signaling alter LAT3 and LAT4 in liver and muscle. These shifts are part of a broader metabolic rewiring in growth and stress.

Immune cells rely on selective transport

T cells increase LAT1 to import leucine at activation. Leucine entry feeds mTORC1, which drives clonal expansion and effector function. Glutamine entry through ASCT2 or SNATs supports nucleotide synthesis and hexosamine biosynthesis. Arginine uptake through CAT1 influences T cell survival and memory formation. Myeloid cells adjust xCT to shape redox tone and cytokine output. This transporter program partly explains why amino acid availability in the tumor microenvironment can suppress immunity.

Brain entry and competition at the blood brain barrier

The blood brain barrier uses LAT1 to move large neutral amino acids. Substrates compete for this shared carrier. Diets that are extremely skewed toward one large neutral amino acid lower entry of others. A practical example appears in classic phenylketonuria care where competition at LAT1 helps limit brain phenylalanine. Another example comes from high dose branched chain mixtures that can lower tryptophan entry because they share the same route. The point is not that competition is always harmful, only that shared transport has predictable tradeoffs at high doses.

Inherited transporter disorders highlight core functions

Hartnup disorder results from loss of SLC6A19 B0AT1. Patients have poor neutral amino acid absorption and reabsorption. Niacin depletion and photosensitive dermatitis can occur because tryptophan, a niacin precursor, is lost in urine and stool.

Cystinuria results from defects in SLC7A9 or SLC3A1, the two partners of the b0,+ transporter. Cystine forms crystals and stones in urine. Management focuses on urine alkalinization, high fluid intake, and thiol drugs in difficult cases.

Lysinuric protein intolerance stems from SLC7A7 defects in y+LAT1. Cationic amino acids do not exit enterocytes or return from kidney tubules well. After protein rich meals patients can develop hyperammonemia because urea cycle function depends on arginine supply. Long term care addresses growth, bone, and lung complications.

These conditions teach the same lesson. Loss of one route does not remove an amino acid from the body entirely because of redundancy. It does create specific bottlenecks that show where each carrier sits in the overall flow.

Cancer, transport, and therapeutic angles

Many tumors raise LAT1 and ASCT2 to import leucine and glutamine. Some raise xCT to maintain glutathione and resist oxidative stress. Others raise SNATs to keep neutral amino acid pools filled under stress. These changes support growth, nucleotide synthesis, and defense against reactive oxygen species. Drugs that block LAT1 or xCT are in study. Nutrient strategies that lower the flux through these routes are also under study as adjuncts. The same redundancy that protects normal tissues can blunt simple “block one door” strategies, which is why combination approaches draw interest.

Do high protein meals saturate transporters

At normal meal sizes intestinal transporters are not the main ceiling for whole body amino acid use. Gut peptidases and PEPT1 allow a high rate of dipeptide and tripeptide absorption even when single amino acid carriers approach saturation. The main limits appear later, in splanchnic extraction by the liver and in the rate at which tissues use amino acids for protein synthesis. A very large single bolus can favor oxidation and urea formation. Spreading protein across the day keeps mixed pools available for muscle and other tissues without stressing one route.

Practical coaching notes that follow from the biology

Protein quality matters because essential amino acids must come from food. Transport does not rescue a diet that lacks essentials. Mixed meals smooth competition at shared carriers. For clients who use large single amino acid supplements, a short separation from other amino acid supplements limits acute competition at shared carriers such as LAT1. People with kidney stones benefit from medical guidance if cystine levels are high because b0,+ transport steps are involved. Clients who take high dose cystine or N acetylcysteine for long periods should have clinician oversight since xCT activity ties directly to glutathione and drug interactions.

Putting the mapping in one place

System L corresponds to SLC7A5 LAT1 and SLC7A8 LAT2 that pair with SLC3A2 4F2hc. System A and N correspond to SLC38 family SNATs. ASCT2 is SLC1A5. Cationic system y+ corresponds to SLC7A1 to SLC7A3. y+L corresponds to SLC7A7 and SLC7A6 with SLC3A2. The brush border broad neutral carrier B0AT1 is SLC6A19. The acidic amino acid carriers EAAT1 to EAAT5 are SLC1A3, SLC1A2, SLC1A1, SLC1A6, and SLC1A7. The cystine exchanger xCT is SLC7A11. PAT1 is SLC36A1. SIT1 is SLC6A20. GlyT1 and GlyT2 are SLC6A9 and SLC6A5. LAT3 and LAT4 are SLC43A1 and SLC43A2.

Common questions

Do individual amino acids ever rely on a single transporter in a given cell type
In some specialized barriers an amino acid may depend heavily on one route. At the blood brain barrier large neutral amino acids rely on LAT1 for entry. In the gut apical neutral amino acid uptake relies strongly on B0AT1. Across the whole body multiple routes still exist.

Can diet shift transporter expression
Yes. Low amino acid intake raises SNAT2 and related genes via ATF4. High leucine can increase exchange flux through LAT1. Chronic inflammation and oxidative stress raise xCT through NRF2. Exercise training increases amino acid use in muscle, and changes in transport often accompany gains in mitochondrial density and capillarization.

Is transporter competition in the brain a real concern in daily life
With normal mixed diets the BBB handles competition well. Extreme single amino acid dosing can lower entry of others that share LAT1. Clinicians use this property in rare disorders, which shows the mechanism is real, but it is not a common concern for healthy people eating mixed meals.

Do transporters only sit on the plasma membrane
Many also sit on organelles. SLC38A9 is on lysosomes and reports arginine levels to the mTOR pathway. Mitochondria import glutamate and aspartate through SLC25 family carriers that are beyond the scope here. Intracellular transport helps balance pools between cytosol and organelles during growth and stress.

Key papers and resources for deeper reading

Review articles on amino acid transport in physiology, oncology, and immunology can be found on PubMed by searching terms such as amino acid transport SLC review, LAT1 cancer review, SNAT2 starvation ATF4, xCT ferroptosis review, and EAAT glutamate uptake review. A good starting point is a broad review by Broer and colleagues on amino acid transport across cell membranes. Readers interested in inherited disorders can search Hartnup disease SLC6A19, cystinuria SLC7A9 SLC3A1, and lysinuric protein intolerance SLC7A7 for patient centered summaries and primary literature links. Gene pages at NCBI and UniProt list aliases and tissue distribution. For concise chemical biology summaries of mTORC1 sensing, search Sestrin2 leucine sensor review and CASTOR arginine sensor review. For immune metabolism search LAT1 T cell activation review and ASCT2 T cell glutamine review. For drug delivery and peptide transport search PEPT1 oral drug absorption review.

A short general source for transporter classifications that stays close to gene names is the IUPHAR/BPS Guide to Pharmacology. That site presents substrate lists and coupling for many SLC members. The Transporter Classification Database curated by Saier and colleagues is an open resource that maps carriers across species and includes references for mechanisms.

Take home points

There is no one transporter per amino acid. Transport is handled by families with overlapping specificity. Redundancy protects cells when diet changes or when one route fails. Polarity in gut and kidney organizes flow from lumen to blood. Sodium and proton coupling pull amino acids in against gradients. Exchange across system L and y+L balances pools without large energy costs. Transport integrates with sensing networks such as mTORC1 and GCN2. Health and disease states shift the mix of carriers. This framework gives you a map for thinking about protein nutrition, supplements, and clinical phenotypes.

Further reading links

PubMed search: amino acid transport review

IUPHAR amino acid transporter family overview

LAT1 and cancer: review articles

xCT SLC7A11 and ferroptosis

SNAT2 and ATF4 during amino acid starvation

EAAT glutamate transporters

B0AT1 and Hartnup disorder

Cystinuria genetics and treatment

Lysinuric protein intolerance

Amino acid transport in immunity